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Amyloid eposits in the islets of Langerhans occur in association with type 2 diabetes mellitus (DM) in humans and 
cats and consist ofa 37-amino-acid polypeptide known as islet amyloid polypeptide (IAPP). In order to find an explana- 
tion for the situation that islet amyloid (IA) does not develop in common rodent species, we have deduced the amino 
acid sequence of the IAPP molecule in mouse, rat and hamster. We find that a specific region of the molecule diverges 
to a high degree. Synthetic peptides corresponding to this region of human and hamster IAPP were compared for their 
ability to form amyloid fibrils in vitro. Whereas the human peptide readily formed fibrils with amyloid character, the 
hamster peptide completely lacked this property. We suggest this to be a likely explanation for the differences in IA forma- 
tion between humans and rodents and discuss our findings in relation to the type 2 DM syndrome. 
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1. INTRODUCTION 
Amyloid deposited in the islets of Langerhans is 
the most characteristic morphologic islet abnor- 
mality in type 2 diabetes mellitus (DM) in humans 
[l-3] and cats [4,5]. This form of amyloid is com- 
posed predominantly of a polymerized 37-amino- 
acid polypeptide called islet amyloid polypeptide 
(IAPP) (also identified as diabetes-associated pep- 
tide, DAP, or amylin), which is homologous with 
neuropeptides of the calcitonin-gene related pep- 
tide (CGRP) family [6-91. cDNA cloning of 
human IAPP indicated that this peptide is a nor- 
mal processing product of an 89-amino-acid pro- 
tein precursor [ 10,111. The amyloidogenic 
properties of human IAPP appear to reside in a 
region spanning amino acid residues 20-29 of the 
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mature molecule in that a synthetic peptide 
representing this region of IAPP spontaneously 
aggregates as amyloid fibrils in vitro [l 1,121. 
Age-associated spontaneous-onset type 2 DM 
occurs only in species that develop islet amyloid 
(IA). The reason for this difference is not known 
but we recently performed immunological 
crossreactivity studies that indicated structural dif- 
ferences in the 20-29 region of IAPP between 
species that do or do not develop IA [I 11. We have 
now determined the primary structure of IAPP in 
three rodent species that do not develop islet 
amyloid and have found a significant amino acid 
divergence in the 20-29 region compared with 
human IAPP. A synthetic peptide corresponding 
to this region of hamster IAPP had quite different 
chemical properties compared to the correspon- 
ding human peptide and did not form amyloid 
fibrils in vitro. Specific differences in amino acid 
sequence of IAPP thus appear to be a major cause 
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of the variation in islet amyloid formation between 
mammalian species and may also be relevant for 
the differences in the development of type 2 DM. 
2. MATERIALS AND METHODS 
2.1. Polymerase chain reactions 
Total cellular RNA was prepared [13] from the hamster and 
rat insulinoma cell lines HIT T15 [14] and RINm4F [IS] as well 
as from mouse pancreas, poly(A) selected on oligo(dT)- 
cellulose (Pharmacia, Uppsala) and converted to single- 
stranded cDNA using oligo(dT) primers as described [16]. Ap- 
prox. 50 ng cDNA was used as template for the enzymatic 
amplification reaction in which a thermostable Thermus 
aquaticus (Taq) DNA polymerase (Perkin Elmer Cetus, Nor- 
walk, CT) and DNA thermal cycler from the same company 
were used. The first two cycles had the profile 94”C, 1 min; 
37”C, 3 min; 72”C, 15 s and the last 28 cycles had the profile 
94°C. 1 min; WC, 2 min; 72”C, 15 s with an extra 5 s at 72°C 
added in each cycle. The following two oligonucleotide primers 
were employed in the reactions: 5’GCAAGCTTAGTCATCA- 
GGTGGAAAAGCG and 5 ’ CGGAATTCTCTACTGCATTC- 
CTCTTGC. The amplification products were analysed on 
agarose Tris-borate buffer gels, cleaved with EcoRI and Hin- 
dIII and subcloned into Ml3 derivatives for sequence analysis 
[17]. Both strands were sequenced on several clones to minimize 
the risk for PCR and sequencing artefacts. 
2.2. Synthetic peptides 
Two peptides corresponding to human and hamster IAPP 
residues 20-29 were synthesized by automated solid-phase syn- 
thesis on an Applied Biosystems model 430A peptide syn- 
thesizer (Applied Biosystems, Foster City, CA). The peptides 
were purified by reversed-phase HPLC on a Nucleosil Cl8 col- 
umn followed by mass pectrometry analysis [18]. The human 
IAPPze-2s was solubilized (5 and 20 mg/ml) in 10% NH40H 
and to the clear solution 0.1 M Tris-HCl was added slowly until 
a gel was formed. In contrast to human IAPPrc-29, hamster 
IAPPrc_29 (5 and 20 mg/ml) easily went into solution in dis- 
tilled water. Adjustment of the pH to acidic (pH 2) or alkaline 
(pH 9) values did not result in any visible alteration in the solu- 
tion. Aliquots of the human and hamster IAPP20-29 solutions 
were dried on glass slides and stained with Congo red. The 
human but not the hamster material had affinity for the dye and 
showed a bright green birefringence after this staining. Small 
droplets of the human and hamster solutions were also applied 
to formvar coated copper grids, negatively contrasted with 1% 
uranyl acetate and studied in a Jeol 2000 EX electron 
microscope at 120 kV. The human material exhibited many 
slightly wavy fine fibrils of about 40 nm width. Often two 
filaments were attached side by side resembling amyloid fibrils. 
In contrast, in the hamster material, only amorphous ubstance 
occurred and no fibrils were seen. 
sense primer 
Hind111 
AGTCATCAGGTGGAAAAGCG 5 10 15 
ysCysAsnThrAlaThrCysAlaThrGlnArRLeuAlaAsnPheLeuValHis 
human .GAAAGTCATCAGGTGGAAAAGCGGAAATGCAACACTGCCACATGTGCAACGCAGCGCCTGGCARATTTTTTAGTTCAT 
hamster 
rat 
G G G C A c c G C 
Arg 
G G G C A A T CCC GC 
Arg 
mouse 
human 
G G G C A A C G G 
20 25 30 35 
Se~rAsnAsnPheGlyAlaIleLeuSerSerThrAsnValG~yS~rA~nThrT~~l~Ly~ArgA=nA~aVa~G~uVa~.. 
TCCAGCAACAACTTTGGTGCCATTCTCTCATCTACCAACGTGGGATCCAATACATAT~CAAGAGGAATGCAGTAGAGGTT.. 
(CGTT- 
Asn Leu ProVal Pro ~TTAAGGC~ 
hamster 
rat 
GA C C GC CA G C G C EcoRI 
anti-sense primer 
Leu ProVal ProPro 
C C AG C C AC A T 
mouse 
Leu ProVal ProPro 
C C AG C C AC R C G C C 
Fig. 1. Comparisons between nucleotide and deduced amino acid sequences of human, hamster, rat and mouse IAPP. (v) N- and C- 
terminals of mature IAPP. The oligonucleotide primers used for PCR are shown. The 20-29 region of mature IAPP is boxed. For 
hamster, rat and mouse, only diverging nucleotides and amino acid residues in comparison with the human are shown. 
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3. RESULTS 
Polymerase chain reaction methodology was 
employed to amplify IAPP sequences in vitro from 
cDNA prepared using mRNA from the hamster in- 
sulinoma cell line HIT T15, the rat insulinoma cell 
line RINmF4 and mouse pancreas. IAPP mRNA 
occurs at very low abundance in all these sources. 
In fact, we have been able to detect a signal on 
RNA blots only with the HIT T15 cell line [l 11. 
Oligonucleotide primers were designed corre- 
sponding to the DNA sequences immediately sur- 
rounding the mature human 37-amino-acid IAPP 
peptide. Their respective 3 ’ ends thus fall within 
the proteolytic cleavage sites surrounding IAPP 
which are likely to be conserved between different 
species. Amplified DNA fragments were subcloned 
into Ml3 derivatives and sequenced. Fig.1 shows 
the resulting hamster, rat and mouse IAPP DNA 
and protein sequences in comparison with human 
IAPP. Whereas the amino-terminal 17 residues 
and the carboxy-terminal 8 residues are identical in 
the four species, substantial divergence is seen be- 
tween residues 18 and 29. Notably, la11 five amino 
acid differences in hamster vs human and five out 
of six diverging positions in rat and mouse fall 
within residues 20-29 of the IAPP molecule. A 
synthetic peptide corresponding to this region in 
human IAPP has previously been shown to form 
fibrils having the characteristics of amyloid as 
judged by ultrastructural morphology and exhibi- 
tion of green birefringence following Congo red 
staining. A synthetic peptide corresponding to the 
same region in hamster completely lacked these 
properties, however (fig.2). This result is in agree- 
ment with the lack of islet amyloid formation in 
hamsters and suggests that amino acid sequence 
differences in the 20-29 region of IAPP are 
Fig.2. Electron micrographs showing synthetic fibrils formed by human IAPPZO-29 (A). Hamster IAPPzo-ZJ (B) did not give rise to 
any amyloid-like fibrils. x 120000. 
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responsible for the observed species-specific pat- 
tern of islet amyloid formation. 
4. DISCUSSION 
The potential role of islet amyloid deposition in 
the pathogenesis of type 2 DM has been largely ig- 
nored in spite of the fact that its occurrence in 
association with the disease was first reported 
almost 90 years ago [20]. Interest in this 
phenomenon has been revived lately through the 
identification of the major amyloid constituent as 
an islet @cell product related to the CGRPs [6-91. 
Subsequently, the demonstration of a biological 
function of IAPP as an inhibitor of insulin- 
stimulated glucose uptake in skeletal muscle cells 
[21] has attracted considerable interest in relation 
to one of the obligatory signs of type 2 DM, 
peripheral insulin resistance (see [22]). The type 2 
DM syndrome also includes a variable defect in in- 
sulin secretion from the &cells [23,24] and we 
recently pointed out that the role of IAPP in type 
2 DM might be dual, i.e. disturbance of islet &cell 
function by its local deposition as amyloid (which 
causes destruction of the &cell membrane and 
which might act as a diffusion barrier) and inhibi- 
tion of the peripheral insulin function through in- 
creased circulating levels of IAPP [25]. The former 
argument is also supported by a correlation bet- 
ween immunological cross-reactivity in the 20-29 
region of IAPP and the observed tendency to 
develop islet amyloid in association with spon- 
taneous maturity-onset DM in different species 
[ 111. The present data show that the amino acid se- 
quence divergence in IAPP occurs almost ex- 
clusively in what has previously been identified as 
the amyloidogenic region of human IAPP. That 
this region of hamster IAPP does not possess in 
vitro amyloidogenic properties highlights the ques- 
tions regarding a possible role of islet amyloid 
deposition in the development of type 2 DM. 
Acknowledgements: This study was supported by grants from 
the Swedish Medical Research Council, the Research Fund of 
King Gustaf V, the Nordic Insulin Fund, the Louis-Hansen’s 
Memorial Fund and the National Institute of Diabetes and 
Digestive and Kidney Diseases. 
REFERENCES 
HI 
121 
131 
[41 
PI 
161 
171 
PI 
[91 
1101 
1111 
WI 
I131 
1141 
WI 
WI 
1171 
WI 
(191 
PO1 
WI 
PI 
1231 
v41 
WI 
Bell, E.T. (1952) Diabetes 1, 341-344. 
Erlich, J.C. and Ratner, I.M. (1961) Am. J. Pathol. 38, 
49-59. 
Westermark, P. (1972) Uppsala J. Med. Sci. 77, 91-94. 
Yano, B.L., Hayden, D.W. and Johnson, K.H. (1981) 
Vet. Pathol. 18, 621-627. 
Johnson, K.H., Hayden, D.W., O’Brien, T.D. and 
Westermark, P. (1986) Am. J. Pathol. 125, 4165-4169. 
Westermark, P., Wernstedt, C., Wilander, E. and 
Sletten, K. (1986) Biochem. Biophys. Res. Commun. 140, 
827-831. 
Westermark, P., Wernstedt, C., Wilander, E., Hayden, 
D.W., O’Brien, T.D. and Johnson, K.H. (1987) Proc. 
Natl. Acad. Sci. USA 84. 3881-3885. 
Westermark, P., Wernstedt, C., O’Brien, T.D., Hayden, 
D.W. and Johnson, K.H. (1987) Am. J. Pathol. 127, 
414-417. 
Cooper, G.J.S., Willis, AC., Clark, A., Turner, R.C., 
Sim, R.B. and Reid, K.B.M. (1987) Proc. Natl. Acad. Sci. 
USA 84, 8628-8632. 
Sanke, T., Bell, G.I., Sample, C., Rubenstein, A.H. and 
Steiner, D.F. (1988) J. Biol. Chem. 263, 17243-17246. 
Betsholtz, C., Svensson, V., Rorsman, F., Engstrom, U., 
Westermark, G.T., Wilander, E., Johnson, K.H. and 
Westermark, P. (1989) Exp. Cell Res., in press. 
Glenner, G.G., Eanes, E.D. and Willey, C.A. (1988) Bio- 
them. Biophys. Res. Commun. 155, 608-614. 
Auffrey, J.C. and Rougeon, F. (1980) Eur. J. Biochem. 
107, 303-314. 
Santerre, R.F., Cook, R.A., Crisel, R.N.D., Sharp, J.D., 
Schmidt, R.J., Williams, D.C. and Wilson, C.P. (1981) 
Proc. Natl. Acad. Sci. USA 78, 4339-4343. 
Gazdar, A.F., Chick, W.L., Oie, H.K., Sims, H.L., 
King, D.L., Weir, G.C. and Lauris, V. (1980) Proc. Natl. 
Acad. Sci. USA 77, 3519-3523. 
Huynh, T.V., Young, R.A. and Davis, R.W. (1986) in: 
DNA Cloning, Vol. 1 (Glover, D.M. ed.) pp.49-78, IRL, 
Oxford. 
Sanger, F., Nicklen, S. and Cot&on, A.R. (1977) Proc. 
Natl. Acad. Sci. USA 74, 5463-5467. 
Sundqvist, B. and MacFarlane, R.D. (1985) Mass 
Spectrometry Rev. 4, 421-460. 
Saiki, R.K., Scharf, S., Faloona, F., Mullis, K.B., Horn, 
G.T. and Erlich, H.A. (1985) Science 230, 1350-1354. 
Opie, E.L. (1900) J. Exp. Med. 5, 397-428. 
Leighton, B. and Cooper, G.J.S. (1988) Nature 335, 
632-635. 
Reaven, G.M. (1988) Diabetes 37, 1595-1607. 
DeFronzo, R.A., Ferrannini, E. and Koisvisto, V. (1983) 
Am. J. Med. 75, 52-81. 
Polonsky, K.S. et al. (1988) N. Engl. J. Med. 318, 
1231-1239. 
Betsholtz, C., Johnson, K.H. and Westermark, P. (1989) 
Nature 338, 211. 
264 
